Clinical trials in Le Chesnay-Rocquencourt – page 116

3 344 clinical trials in Le Chesnay-Rocquencourt, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Le Chesnay-Rocquencourt at a glance

3 344

clinical trials

Research sites1

Quick filters

3 344 trials in Le Chesnay-Rocquencourt

Open in trial search

Primary biliary cholangitis

Not yet recruiting

Safety and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis: A Long‑Term Randomized Placebo‑Controlled Study

Investigational

Safety and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis: A Long‑Term Randomized Placebo‑Controlled Study

Investigational

France

Participants:18–64 years
Substances:Saroglitazar hemimagnesium
Sponsor:Zydus Therapeutics Inc.

Contact Research Centre

Retinal dystrophy

Not yet recruiting

A Study of ATSN-201 Gene Therapy for Patients with X-linked Retinoschisis (RS1-associated) to Assess Safety and Visual Function

InvestigationalNo placebo

A Study of ATSN-201 Gene Therapy for Patients with X-linked Retinoschisis (RS1-associated) to Assess Safety and Visual Function

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Ziloretgene parvec
Sponsor:Atsena Therapeutics Inc.

Contact Research Centre

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

France

Participants:18–64 years · 65+ years
Substances:DNTH103
Sponsor:Dianthus Therapeutics Inc.

Contact Research Centre

Septic shock

Not yet recruiting

Efficacy of dapagliflozin in adult patients with septic shock and microcirculatory dysfunction

Registered drug

Efficacy of dapagliflozin in adult patients with septic shock and microcirculatory dysfunction

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Dapagliflozin
Sponsor:Les Hopitaux Universitaires De Strasbourg

Contact Research Centre

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

Registered drugNo placebo

Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Nemtabrutinib
Sponsor:French Innovative Leukemia Organization

Contact Research Centre

Clear cell renal cell carcinoma+2

Not yet recruiting

Phase 1/2 Study of pumitamig Alone or Combined with ipilimumab or cabozantinib in Patients with Advanced Renal Cell Carcinoma

Registered drugNo placebo

Phase 1/2 Study of pumitamig Alone or Combined with ipilimumab or cabozantinib in Patients with Advanced Renal Cell Carcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Sickle cell disease

Not yet recruiting

A study of etavopivat to reduce vaso‑occlusive crises in children with sickle cell disease

Investigational

A study of etavopivat to reduce vaso‑occlusive crises in children with sickle cell disease

Investigational

France

Participants:0–17 years
Substances:Etavopivat
Sponsor:Novo Nordisk A/S

Contact Research Centre

Endometrial cancer

Not yet recruiting

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:GSK5733584
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Idiopathic pulmonary fibrosis

Not yet recruiting

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Deupirfenidone
Sponsor:Celea Therapeutics Inc.

Contact Research Centre

Colorectal cancer metastatic

Not yet recruiting

Second‑line ivonescimab plus chemotherapy drug combination versus bevacizumab in patients with metastatic colorectal cancer without liver metastases

Registered drugNo placebo

Second‑line ivonescimab plus chemotherapy drug combination versus bevacizumab in patients with metastatic colorectal cancer without liver metastases

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Unicancer

Contact Research Centre

Gaucher's disease type III

Not yet recruiting

Efficacy and safety of oral venglustat versus intravenous imiglucerase in children aged 2‑11 years with Gaucher disease type 3

Registered drugNo placebo

Efficacy and safety of oral venglustat versus intravenous imiglucerase in children aged 2‑11 years with Gaucher disease type 3

Registered drugNo placebo

France

Participants:0–17 years
Substances:Imiglucerase
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Colon cancer+3

Not yet recruiting

Effect of a multidisciplinary care pathway on safety of oral anticancer therapy in patients aged ≥70 with cancer (capecitabine and drug combination)

Registered drugNo placebo

Effect of a multidisciplinary care pathway on safety of oral anticancer therapy in patients aged ≥70 with cancer (capecitabine and drug combination)

Registered drugNo placebo

France

Participants:65+ years
Substances:Abemaciclib
Sponsor:Institut Gustave Roussy

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Le Chesnay-Rocquencourt

What the registry says about research in the country

01 Cardiology & Respiratory Medicine

Clinical trials focusing on acute myocardial infarction pain management and innovative treatments for severe asthma. Research includes evaluation of novel pain-relief methods and assessment of treatment discontinuation strategies.

Pain management in heart attacks
Asthma treatment optimization
Heart failure management

Studies also examine beta-blocker discontinuation in patients with recovered heart function.

02 Oncology & Hematology

Extensive research in blood cancers, including multiple myeloma, acute myeloid leukemia, and various lymphomas. Studies evaluate novel drug combinations and treatment strategies.

Blood cancer therapies
Leukemia treatments
Breast cancer management

Investigations include targeted therapies and personalized treatment approaches for various cancer types.

03 Pediatric & Infectious Diseases

Research focusing on respiratory syncytial virus (RSV) prevention in infants and children. Studies evaluate new protective treatments and their safety profiles.

RSV prevention
Infant protection studies
Immunotherapy research

Trials include assessment of novel medications for preventing severe respiratory infections in vulnerable populations.

Back to France All countries